Does HRT affect risk of blood clots today?

The short answer: Yes, estrogen can increase blood clot risk, but current clinical understanding distinguishes which formulations raise the risk, which do not, and how HRT can be used appropriately for many women. The increased risk comes mainly from oral estrogen pills. Modern transdermal estrogen (patch, gel, spray) has little to no measurable clot risk for most women, according to current clinical guidelines.

How HRT affects clot risk today

Per FDA-approved prescribing information, estrogen-containing products carry a black box warning noting increased risk of deep vein thrombosis, pulmonary embolism, and stroke. These risks are relevant to all forms of systemic estrogen and should be considered when evaluating HRT options.

The mechanism by which oral estrogen increases clot risk relates to hepatic metabolism. According to current NAMS guidelines, when estrogen is taken orally, it passes through the liver before entering systemic circulation, stimulating production of clotting factors and thereby increasing the risk of deep vein thrombosis or pulmonary embolism.

With transdermal estrogen, the hormone is absorbed through the skin directly into the bloodstream, bypassing hepatic first-pass metabolism. Per published clinical guidelines, transdermal estrogen does not meaningfully alter clotting factor levels. Current evidence indicates transdermal estrogen is associated with little to no increased clot risk compared to oral estrogen, including in women with moderately elevated baseline risk factors such as hypertension or elevated body weight.

Adding progesterone does not typically contribute to clot risk. According to current NAMS guidelines, micronized progesterone has a neutral clot profile. Compounded transdermal or oral formulations may behave similarly, but potency and consistency can vary between preparations.

Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

What this means for clinical decision-making

• If using a patch, gel, or spray: Per published clinical guidelines, current research does not show a meaningful increase in clot risk for most women using transdermal estrogen.
• If using an oral estrogen pill: Per FDA-approved prescribing information, there is a small but real increase in clot risk, comparable to that seen with some combined oral contraceptives.
• Progesterone: According to NAMS guidelines, micronized progesterone is considered to have a neutral effect on clot risk.
• Personal risk factors: A history of prior clotting events, a confirmed clotting disorder, or significantly elevated clot risk may affect suitability for HRT. Per the Endocrine Society, individual risk assessment is essential before initiating hormone therapy.

Whether HRT is appropriate for individuals with concerns about blood clot risk depends on many personal health factors that cannot be assessed through website content alone. A prescriber should determine the best approach based on a patient's complete medical history, including any prior clotting events, current medications, and individual cardiovascular risk profile.